Wire Stories

Chinese Health Care Markets Report 2022: Demand for Health Care will continue to grow at about 11% by 2031 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Health Care Markets in China" report has been added to ResearchAndMarkets.com's offering.

Focus on China's Healthcare for 1.3 Billion People

In the two past decades, the healthcare industry has been growing at a fast pace. It is a tremendous challenge to provide healthcare for 1.3 billion people. The dramatic expansions of the healthcare system, drug manufacturing, and health insurance have transformed China's society and economy.

Life expectancy reached 76.8 for women and 72.5 for men now comparing to 69.9 for women and 66.9 for men in 1990. Demographic transition from high mortality to low mortality has helped increase life expectancy. Primary diseases have also shifted from infectious to chronic. Cancer, heart diseases and cerebrovascular diseases are now top killers. Spending on healthcare counts for over 5% of GDP now and continue to increase in the next decade.

Healthcare reform has been one of the key topics on the government agenda in China. Due to the rise in the cost of healthcare, more than 10% of the income is spent on healthcare, which is greater than that spent on education and transportation. The rise in the cost in healthcare would definitely have an outcome of the high cost of the drugs.

There are approximately 4,500 pharmaceutical companies in China, the majority of which are small players with limited local market reach. Rapid consolidation between medium and large players in the sector is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to better control the pricing of drugs.

Biotechnology is a rapidly growing sector in China. Both production and demand have witnessed significant surges in recent years. China will continue to remain a large importer for biotechnology pharmaceuticals to meet the growing domestic demand. Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.

The health care insurance industry of China includes two main parts such as the social healthcare insurance controlled by the government and commercial healthcare insurance provided by private companies. At present, the social healthcare insurance is under reforms to control the increasing healthcare costs. The development of commercial healthcare insurance in China is not inadequate. But the commercial healthcare insurance market has a great growth potential. Today, China has the largest healthcare market in the world. The Chinese healthcare industry is one of the fastest-growing sectors in China, growing at double digit rate each year. Tremendous fast-growing markets for imports and business opportunities for companies around the world.

Key Topics Covered:

I. INTRODUCTION

II. BUSINESS ENVIRONMENT

  • Economic Outlook
  • Key Economic Indicators
  • Industrial Output
  • Population and Labor
  • Foreign Investment
  • Foreign Trade
  • Financial and Tax Regulations
  • Banking System and Regulations
  • Foreign Exchange
  • Taxes, Tariff and Custom Duties

III. HEALTH CARE INDUSTRY ASSESSMENTS

  • Health Care Industry Structure
  • Market Size
  • Major Producer Facility Locations and Output
  • Market Share of Key Producers
  • Labor Costs
  • Potential Entrants
  • Major Distributors
  • Major Foreign Investments
  • Technology Development

IV. HEALTH CARE INDUSTRY OUTPUTS AND FORECASTS

  • Overview
  • Medical Treatment Revenues and Forecasts by Region
  • Northeast

    • Hospitals
    • Physicians
    • Hospital Visits
    • Medical Treatment Revenues
  • North
  • Southeast
  • Central South
  • Southwest
  • Northwest
  • Medical Supplies Production and Demand
  • Major Producers
  • Total Output and Demand
  • Foreign Trade
  • Pricing Trends
  • Output and Demand by Region
  • Pharmaceuticals Production and Demand
  • Major Producers
  • Total Output and Demand
  • Foreign Trade
  • Pricing Trends
  • Output and Demand by Region
  • Medical Equipment Production and Demand
  • Major Producers
  • Total Output and Demand
  • Foreign Trade
  • Pricing Trends
  • Output and Demand by Region

V. HEALTH CARE MARKET OUTLOOKS

  • Health Care Markets Outlook Overview
  • Government Health Care Regulations
  • Health Care Insurance Industry Overview
  • China's Population Overview
  • Population by Region
  • Northeast
  • North
  • Southeast
  • Central South
  • Southwest
  • Northwest
  • Population by Age Group
  • Consumer Spending Trends

VI. MARKETING STRATEGIES

  • China Market Entry Overview
  • China's Distribution System
  • Health Care Industry Distribution Channels
  • Transportation and Freight Infrastructure
  • Communications
  • China's Market Entry
  • Licensing
  • Franchising
  • E-commerce
  • Trading Companies and Local Agents
  • Representative Offices and Chinese Subsidiaries
  • Wholly Foreign Owned Enterprise

VII. HEALTH CARE PRODUCER DIRECTORY

LIST OF TABLES

I. INTRODUCTION

  • Economic Outlook Summary

II. BUSINESS ENVIRONMENT

  • Key Economic Indicators
  • Industrial Output
  • Population and Labor Force Trends
  • Foreign Investment and Loans
  • Foreign Trade

III. HEALTH CARE INDUSTRY ASSESSMENTS

  • Major Producer Facility Locations and Output
  • Market Share of Key Producers
  • Major Distributors
  • Major Foreign Investments

IV. HEALTH CARE INDUSTRY OUTPUTS AND FORECASTS

  • The Total Health Care Output and Demand
  • The Major Producers of Medical Supplies
  • The Total Medical Supplies Output and Demand
  • The Foreign Trade of Medical Supplies
  • The Major Producers of The Pharmaceuticals
  • The Pharmaceuticals Total Output and Demand
  • The Foreign Trade of the Pharmaceuticals
  • The Major Producers of Medical Equipments
  • The Medical Equipment Total Output and Demand
  • The Foreign Trade of the Medical Equipment

V. HEALTH CARE MARKET OUTLOOKS

Companies Mentioned

  • Huabei Pharmaceutical Group Co., Ltd.
  • Shijiazhuang Pharmaceutical Group Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/mbv01b

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

To Top